Weqas
Unit 6, Parc Tŷ Glas,
Llanishen
Cardiff, UK
CF14 5DU
Tel: +44 (0) 2920 314750
Fax: +44 (0) 2920 314760
E-mail: office@weqas.com

Urine Drugs of Abuse EQA

INTENDED USE

Weqas Urine Drugs of Abuse (DoA) EQA samples are for in-vitro diagnostic use as an external quality assessment material for testing of Drugs of Abuse in Urine.

SUMMARY

External Quality Assessment (EQA), or proficiency Testing (PT) is an essential part of providing quality laboratory diagnostic services, and participation in EQA is required for laboratory accreditation to ISO 15189 and ISO 17025. EQA is the inter laboratory comparison and performance evaluation that extends throughout all phases of the healthcare diagnostic testing cycle.

PRODUCT DESCRIPTION

3.0 mL volume supplied in sterile plastic tubes. The material has been prepared from sterile urine from healthy donors, with an antibiotic added to maintain sterility. The urine is dispensed and stored at -20°C until dispatch.

STORAGE AND STABILITY

Unopened samples are stable for two (2) weeks in a refrigerator at 2-8°C.

The samples should be assayed on the day you receive them. If you are unable to assay the samples immediately upon receipt, please store at 2-8°C until analysis. Samples stored at 2-8°C prior to analysis must be brought to room temperature and assayed within 1 hour.

PROCEDURE

The samples should be treated the same as patient specimens and run in accordance with the instructions accompanying the test system being used.

1. Mix the sample well by gently inverting 5 to 6 times.
2. Wear gloves and handle the sample as a normal patient sample.
3. Safely dispose of excess sample in accordance with local waste policy guidelines.

Always wear gloves to avoid contamination.

STORAGE AND PROCEDURE FOR BATCHED SAMPLES

The samples should be stored at -20°C on receipt. At the start of the return window for each distribution thaw the relevant samples at room temperature for 24 hours (maximum 48 hours) and assay as described in PROCEDURE.

Please ensure that the samples are well mixed before analysis

LIMITATIONS OF PROCEDURE

The Urine Drugs of Abuse EQA samples should be analysed according to the instructions within this document. If there is evidence of microbial contamination or excessive turbidity in the product, discard the vial.

The Urine Drugs of Abuse EQA samples require storage as described in STORAGE AND STABILITY and handling as described in PROCEDURE.

Accurate and reproducible results are dependent upon properly functioning instruments and reagents and the use of correct procedures.

APPROXIMATE RANGE COVERED

The Weqas Urine Drugs of Abuse EQA samples cover a relevant pathological and analytical range as outlined on page 2.

! CAUTION !

Human source material.
The base material is sterile human urine from healthy donors.

Although every effort is made to ensure that the material is free from any known infectious agent, the samples should be handled as for clinical specimens.

APPROXIMATE ANALYTE RANGE COVERED

Analyte	Approx Range (µg/L)
Amphetamine	0 – 3000
Amphetamines Group Screen	Neg / Pos
Cannabis	0 - 150
Opiates	0 - 3000
Benzodiazepines	0 - 1000
Cocaine	0 - 1000
Methadone	0 - 1000
EDDP	0 - 1000
Methamphetamine	0 - 3000
Heroin	0 - 50
Buprenorphine	0 - 50
Ketamine	0 - 3000
Barbiturates	0 - 1000
MDMA	0 – 3000
Phencyclidine	0 – 100
Tricyclic Anti-Depressants	0 - 3000